AU708032B2 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis Download PDF

Info

Publication number
AU708032B2
AU708032B2 AU63050/96A AU6305096A AU708032B2 AU 708032 B2 AU708032 B2 AU 708032B2 AU 63050/96 A AU63050/96 A AU 63050/96A AU 6305096 A AU6305096 A AU 6305096A AU 708032 B2 AU708032 B2 AU 708032B2
Authority
AU
Australia
Prior art keywords
oxoazetidin
diastereoisomer
acetamide
ylacetamide
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63050/96A
Other languages
English (en)
Other versions
AU6305096A (en
Inventor
Dashyant Dhanak
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
David Graham Tew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU6305096A publication Critical patent/AU6305096A/en
Publication of AU708032B2 publication Critical patent/AU708032B2/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU63050/96A 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis Ceased AU708032B2 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GB9513442 1995-07-01
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GB9515056 1995-07-22
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GB9515206 1995-07-25
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GB9516985 1995-08-18
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GB9525132 1995-12-08
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds
GB9608650 1996-04-26
GB9608651 1996-04-26
PCT/EP1996/002765 WO1997002242A1 (fr) 1995-07-01 1996-06-20 Derives de l'azetidinone pour le traitement de l'atherosclerose

Publications (2)

Publication Number Publication Date
AU6305096A AU6305096A (en) 1997-02-05
AU708032B2 true AU708032B2 (en) 1999-07-29

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63050/96A Ceased AU708032B2 (en) 1995-07-01 1996-06-20 Azetidinone derivatives for the treatment of atherosclerosis

Country Status (23)

Country Link
EP (1) EP0840725A1 (fr)
JP (1) JP2002515852A (fr)
KR (1) KR19990028630A (fr)
CN (1) CN1197452A (fr)
AP (1) AP728A (fr)
AU (1) AU708032B2 (fr)
BG (1) BG102214A (fr)
BR (1) BR9609445A (fr)
CA (1) CA2225627A1 (fr)
CZ (1) CZ422197A3 (fr)
EA (1) EA199800109A1 (fr)
HU (1) HUP9901153A3 (fr)
IL (1) IL122650A0 (fr)
MA (1) MA23922A1 (fr)
MX (1) MX9800186A (fr)
NO (1) NO976158L (fr)
NZ (1) NZ311684A (fr)
OA (1) OA10648A (fr)
PE (1) PE8998A1 (fr)
PL (1) PL324240A1 (fr)
SK (1) SK178497A3 (fr)
TR (1) TR199701762T1 (fr)
WO (1) WO1997002242A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (fr) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
NZ332476A (en) * 1996-04-26 2000-06-23 Smithkline Beecham Plc substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
NZ520752A (en) 2000-02-16 2004-03-26 Smithkline Beecham P Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
KR101690390B1 (ko) 2007-05-11 2016-12-27 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
CA2687079A1 (fr) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Procedes de traitement des ulceres de la peau
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドGlaxo Group Limited Lp−PLA2により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
EP2651403B1 (fr) 2010-12-17 2020-12-02 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
EP2736908A1 (fr) 2011-07-27 2014-06-04 Glaxo Group Limited Composés pyrimidones bicycliques
CA2842965A1 (fr) 2011-07-27 2013-01-31 Glaxo Group Limited Composes 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
RU2015135824A (ru) 2013-01-25 2017-03-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Бициклические соединения пиримидона в качестве ингибиторов lp-pla2
ES2642762T3 (es) 2013-01-25 2017-11-20 Glaxosmithkline Intellectual Property Development Limited Inhibidores de fosfolipasa A2 asociada a lipoproteínas (LP-PLA2) basados en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1H)-ona
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
CA3156783A1 (fr) 2019-11-09 2021-05-14 Yun Jin Derive de dihydroimidazopyrimidone tricyclique, son procede de preparation, composition pharmaceutique et son utilisation
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
MA23834A1 (fr) * 1994-12-22 1996-10-01 Smithkline Beecham Plc Procede de preparation de composes inhibiteurs de l'enzyme lp-pla2 et de compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
HUP9901153A2 (hu) 1999-08-30
BR9609445A (pt) 1999-04-06
TR199701762T1 (xx) 1998-05-21
PL324240A1 (en) 1998-05-11
MA23922A1 (fr) 1996-12-31
BG102214A (en) 1998-08-31
IL122650A0 (en) 1998-08-16
EP0840725A1 (fr) 1998-05-13
WO1997002242A1 (fr) 1997-01-23
SK178497A3 (en) 1998-07-08
CZ422197A3 (cs) 1998-06-17
JP2002515852A (ja) 2002-05-28
NO976158D0 (no) 1997-12-30
NO976158L (no) 1998-02-25
AP9701161A0 (en) 1998-01-31
MX9800186A (es) 1998-07-31
OA10648A (en) 2002-09-25
NZ311684A (en) 2000-04-28
KR19990028630A (ko) 1999-04-15
EA199800109A1 (ru) 1998-10-29
CA2225627A1 (fr) 1997-01-23
CN1197452A (zh) 1998-10-28
AU6305096A (en) 1997-02-05
HUP9901153A3 (en) 1999-11-29
AP728A (en) 1999-01-29
PE8998A1 (es) 1998-03-20

Similar Documents

Publication Publication Date Title
AU708032B2 (en) Azetidinone derivatives for the treatment of atherosclerosis
US6071899A (en) Azetidinone derivatives for the treatment of atherosclerosis
US5990102A (en) Substituted azetidin-2-ones for treatment of atherosclerosis
KR100338171B1 (ko) 저콜레스테롤형증제로서유용한치환된아제티디논화합물
NZ243669A (en) Heterocyclyl-substituted beta-lactam derivatives pharmaceutical compositions
JP2000505063A (ja) アテローム性動脈硬化症の治療のためのアゼチジノン化合物
JP2000509049A (ja) アテローム性動脈硬化症の治療用アゼチジノン誘導体
TWI739206B (zh) 二氫嘧啶-2-酮化合物及其醫藥用途
JP2000509063A (ja) アテローム性動脈硬化症の治療用アゼチジノン誘導体
EP0869943A1 (fr) Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
JPH05279367A (ja) β−ラクタム誘導体の製法
FR2524890A1 (fr) Nouveaux derives de carbapenem, compositions pharmaceutiques les contenant, composes intermediaires pour leur preparation, et leurs procedes de production
RU2214409C2 (ru) N-фениламидные и n-пиридиламидные производные, способ их получения и содержащие их фармацевтические композиции
JPS58134074A (ja) 抗菌剤、その製法及びそれを含む医薬組成物
JPH0780840B2 (ja) 4,4‐ジアルキル‐2‐アゼチジノン類の製造法
EP0658550A2 (fr) Sels d'acide aminé de composés de tétrazole ayant une activité antihypercholestérolémique et procédés pour leur préparation
FR2552763A1 (fr) Nouveaux derives du carbapeneme, leur preparation et leur utilisation comme medicaments
JPH04117382A (ja) 1―メチルカルバペネム誘導体及びその製法
KR20000065040A (ko) 아테롬성동맥경화증치료를위한아제티디논유도체
JPH0123460B2 (fr)
MXPA98008924A (en) Azetidinone derivatives for deeterosclero treatment

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired